Here are 8 of the Top Performing ASX Stocks in 2025 (excluding resources)!

Yesterday, we recapped the Top Performing ASX Stocks in 2025 but the list was dominated by resources companies. Today, we recap the best non-resources ASX stocks in 2025!

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips.

The 8 Top Performing ASX Stocks in 2025

EDU Holdings (ASX:EDU)

EDU operates in the education sector, primarily through the Ikon Institute, a specialist tertiary education provider. EDU’s 2025 momentum has been driven by stronger enrolments, particularly from international students, and upgraded FY25 guidance predicting higher revenue, EBITDA and profit versus FY24, signalling operational momentum post-pandemic. These strategic actions — revenue growth and disciplined capital management — have supported its share price gains even against broader regulatory uncertainty about potential caps on international student numbers in Australia.

iSynergy (ASX:IS3)

iSynergy is a technology and digital solutions company originally focused on performance-based affiliate marketing via its VTRAK platform connecting advertisers and affiliates across Southeast Asia. In 2025 the company drove investor interest by entering new strategic arrangements, notably a strategic partnership with Octagram and a GPU/AI infrastructure agreement with a US-listed partner (Treasure Global) aimed at expanding its technology capabilities.

These deals are part of iSynergy’s pivot from pure affiliate services toward broader digital/AI-capable offerings, a narrative that can fuel re-rating in small-cap tech names. Insider share buying reported in late 2025 indicates confidence among directors following these strategic shifts, although the stock has also seen volatility.

Almonty Industries (ASX:AII)

Almonty is a global tungsten producer with assets in several countries including the Sangdong Mine (South Korea), historically one of the largest tungsten mines outside China. The company reported spectacular financial results showing strong strategic positioning as a critical minerals supplier targeted by defence and industrial supply-chain diversification policies, including agreements to supply tungsten oxide for US defence applications and participation in US critical minerals forums.

Almonty also completed dual-listed on the NASDAQ, raising US$90m in the process and opened it up to American investor. While the company is not yet profitable (even largely due to non-cash accounting revaluations), the underlying supply-chain narrative and financing milestones have supported share performance

Artrya (ASX:AYA)

This company has not missed a beat since its mid-April FDA approval. Its Salix suite of products (led by the Salix Coronary Anatomy or SCA) aim to improve the detection and treatment of Coronary Artery Disease (CAD), which is a major cause of heart attacks, and it does so via detecting vulnerable plaque…via AI. SCA just needs an internet connection, there’s no hardware required and a full report is available within 15 minutes. It can be installed remotely and can come with the option of a single flat fee per image scanned.

The FDA green light was always going to be a catalyst. But what also helped is that Artrya already had strategic agreements with 3 US hospital groups which have already worked to integrate Salix into its workflows in anticipation of approval. It raised $75m later in the year to facilitate the rollout.

Elsight (ASX:ELS)

Elsight develops connectivity hardware and software for autonomous systems, particularly for drones and unmanned platforms. Its technology enables resilient communications (e.g., 5G, LTE, satellite) for mission-critical applications, an attractive space amidst rising demand for autonomous and defence-oriented systems. Growth in demand for its modules, expanded sales, strategic partnerships and entry into rapidly evolving markets have been key drivers for share price performance in 2025. But unlike others in this space, it has not had any particularly noteworthy deals that could explain its individual performance.

Lumos Diagnostics (ASX:LDX)

Lumos is the company behind FebriDx is the only rapid, all-in-one point-of-care test on the planet that can distinguish a clinically significant acute respiratory infection (ARI) and differentiate viral from bacterial infections. Back in July, Lumos announced a pivotal, exclusive US supply and distribution deal for FebriDx valued at up to US$317m/A$487m from PHASE Scientific International. Under the terms of the deal, Lumos received a US$1m non-refundable exclusivity payment on signing and was promised US$7.5m in non-refundable prepaid purchase orders.

The total value could be US$317m if all payment milestones aforementioned and minimum order quantities are met. This is one of the largest distribution deals of its type to be done by an ASX-listed point of care company.

Nyrada (ASX:NYR)

Nyrada is a clinical-stage ASX biotech company developing small-molecule therapies for conditions such as brain injury, stroke and cardiac injury. Its lead candidate, Xolatryp, has shown promising preclinical results, such as cardioprotection and reduced arrhythmias in animal models, and passed Phase I where it passed the safety and tolerability benchmarks.

Now Nyrada is focused on advancing it into a Phase IIa trial where it will be tested in partients with ST-Elevation Myocardial Infarction (STEMI) who undergo a heart surgery known as Percutaneous Coronary Intervention (PCI).

Electro Optic Systems (ASX:EOS)

EOS is a defence and space technology company, specialising in counter-drone systems, remote weapon stations, high-energy laser weapons and other advanced technologies.

In 2025, the company has secured major defence contracts, including for next-generation counter-drone systems and export orders, driving strong revenue prospects and positioning the business as a beneficiary of rising defence spending and security priorities. The August announcement of the world’s first export of a 100 kW laser anti-drone weapon system to an undisclosed NATO European country, catalysed a surge in its share price.

The landmark order positions EOS at the forefront of laser-based defence solutions; it’s likely to pursue naval variants and higher-power (150 kW) systems. With no borrowings and substantial cash reserves, the company is now well positioned to fund future expansion in its core Defence and Space Systems segments without being constrained by debt servicing.